论文部分内容阅读
目的探讨妊娠合并卵巢肿瘤的孕期监测及临床处理方法。方法回顾性分析2005年1月至2010年1月我院发现孕期合并卵巢肿瘤者105例,其中孕期及剖宫产术中明确诊断并经手术病理证实的妊娠合并卵巢肿瘤者38例,占同期确诊妊娠合并卵巢肿瘤的36.1%。结果妊娠合并卵巢肿瘤的发生率为2.2%,所有病例均做B超检查并定期监测,部分病例免疫监测糖链抗原CA125(CA125)、癌胚抗原(CEA)、甲胎蛋白(AFP)升高,本组病例均经手术和病理明确诊断,卵巢肿瘤病理类型分布同非孕期,其中以成熟囊性畸胎瘤最为多见,占68.5%(26/38)。结论应加强妊娠前及妊娠早期的妇科检查,B超对妊娠期卵巢肿瘤的诊断价值较高;免疫测定CA125、CEA、AFP可协助判断卵巢肿瘤的良恶性;肿瘤手术时间应选择在妊娠16~20周为宜。
Objective To investigate the pregnancy monitoring and clinical treatment of pregnancy with ovarian tumors. Methods A retrospective analysis from January 2005 to January 2010 in our hospital found that 105 cases of ovarian cancer during pregnancy, pregnancy and cesarean section in which a clear diagnosis and confirmed by surgical pathology in 38 cases of pregnancy with ovarian tumors, accounting for the same period 36.1% of pregnancies with ovarian tumors were diagnosed. Results The incidence of pregnancy complicated with ovarian cancer was 2.2%. All the cases were monitored by B ultrasound and monitored regularly. Some of the cases showed increased CA125, CEA and AFP The cases were diagnosed by operation and pathology. The distribution of ovarian tumor pathology was the same as that of non-pregnancy, of which mature cystic teratoma was the most common, accounting for 68.5% (26/38). Conclusions Gynecological examination should be strengthened before pregnancy and in early pregnancy, B ultrasound diagnosis of ovarian tumors in pregnancy is higher; immunoassay CA125, CEA, AFP can help determine the ovarian cancer benign and malignant; tumor operation time should be selected in pregnancy 16 ~ 20 weeks is appropriate.